Top of the morning to you, and a fine one it is. Relatively mild temperatures and clearing skies this morning are livening the Pharmalot campus, where things have quieted down now that our short people have departed for their endeavors. This leaves us to our own devices, notably the coffee kettle, which we are firing up again to enjoy some cups of stimulation. Our choice today is pecan pie. Feel free to choose something equally provocative and join us. Meanwhile, here are some tidbits. Hope your journey today is a smooth one and, as always, do keep in touch …

And then there were five — pharma execs, that is, who have agreed to appear at a Senate Finance Committee hearing later this month to discuss drug prices. Among them: Merck (MRK), Pfizer (PFE), Sanofi (SNY), Bristol-Myers Squibb (BMY), and the Janssen unit of Johnson & Johnson (JNJ). Their scheduled appearances will follow an upbraiding from Sen. Chuck Grassley (R-Iowa), who chairs the committee, and Sen. Ron Wyden (D-Ore.), who chastised the executives for failing to testify at a recent hearing on the subject.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy